The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

Deaths from heart failure have been climbing steadily since 2012. Drugs to treat the 2 main types of heart failure aren't ...

Heart failure; LVEF: Left ventricular ejection fraction; MERIT-HF: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; NA: Not available; SENIORS: Study of the Effects of ...

A groundbreaking study shows how Zepbound, a popular weight loss medication, could become a key treatment for heart failure ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

IRH linked to incident heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction ...

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

AISAP, a medical technology company developing AI-powered Point-of-Care Assisted Diagnosis (POCAD™) solutions to transform ...